Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

461. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis McCurdy BR Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(10). 2012 Authors' objectives The objective of this analysis was to compare hospital-at-home care with inpatient hospital care for patients with acute

2012 Health Technology Assessment (HTA) Database.

462. Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based (...) analysis COPD Working Group Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation COPD Working Group. Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(9). 2012 Authors' objectives

2012 Health Technology Assessment (HTA) Database.

463. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis

been made for the HTA database. Citation COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(6). 2012 Authors' objectives The objective of this evidence-based review was to determine the effectiveness and cost-effectiveness of pulmonary rehabilitation in the management of chronic obstructive pulmonary disease (COPD). Authors' conclusions Based on low-quality evidence (...) Pulmonary Disease, Chronic Obstructives; Recovery of Function; Respiratory Function Tests Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Medical Advisory Secretariat, Ontario Ministry of Health and Long Term Care, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 Canada Email: MASinfo.moh@ontario.ca AccessionNumber 32012000629 Date abstract record published 19/09/2012 Health

2012 Health Technology Assessment (HTA) Database.

464. Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis COPD Working Group Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation COPD Working Group. Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(7). 2012 Authors' objectives The objective of this health technology assessment was to determine the effectiveness, cost-effectiveness, and safety of long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD). Authors

2012 Health Technology Assessment (HTA) Database.

465. Experiences of living and dying with COPD: a systematic review and synthesis of the qualitative empirical literature

of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Giacomini M, DeJean D, Simeonov D, Smith A. Experiences of living and dying with COPD: a systematic review and synthesis of the qualitative empirical literature. Toronto: Medical Advisory Secretariat (MAS). Volume 12(13). 2012 Authors' objectives The objective of this analysis was to review empirical qualitative research on the experiences of patients with chronic obstructive pulmonary disease (COPD (...) ), informal caregivers ("carers"), and health care providers—from the point of diagnosis, through daily living and exacerbation episodes, to the end of life. Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Pulmonary Disease, Chronic Obstructive; Qualitative Research; Terminally Ill Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence

2012 Health Technology Assessment (HTA) Database.

466. Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Franek J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Franek J. Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(11). 2012 Authors' objectives The objective of this analysis was to conduct an evidence-based assessment of home telehealth technologies for patients with chronic obstructive pulmonary disease (COPD) in order to inform recommendations regarding the access and provision of these services

2012 Health Technology Assessment (HTA) Database.

467. Chronic obstructive pulmonary disease (COPD) evidentiary framework

Chronic obstructive pulmonary disease (COPD) evidentiary framework Chronic obstructive pulmonary disease (COPD) evidentiary framework Chronic obstructive pulmonary disease (COPD) evidentiary framework OHTAC COPD Collaborative Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (...) (COPD) evidentiary framework. Toronto: Medical Advisory Secretariat (MAS). Volume 12(2). 2012 Authors' objectives The objective of this report series is to create an evidentiary base and economic analysis that will guide investment in the treatment of chronic obstructive pulmonary disease (COPD) in a way that optimizes patient outcomes and system efficiencies. This evidentiary platform concerning the effectiveness and cost-effectiveness of treatment strategies for patients with COPD will be used

2012 Health Technology Assessment (HTA) Database.

468. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model Chandra K, Blackhouse G, McCurdy BR, Bornstein M, Campbell K, Costa V, Franek J, Kaulback K, Levin L, Sehatzadeh S, Sikich N, Thabane M, Goeree R Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chandra K, Blackhouse G, McCurdy BR, Bornstein M, Campbell K, Costa V, Franek J, Kaulback K, Levin L, Sehatzadeh S, Sikich N, Thabane M, Goeree R. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Toronto: Medical Advisory Secretariat (MAS

2012 Health Technology Assessment (HTA) Database.

469. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Tiotropium appears to help improve objective lung function test measures, reduce (...) the proportion of patients with =1 exacerbation, and improve COPD-related symptoms. There were conflicting results between the two included reports regarding a reduction in frequency of exacerbations. The use of tiotropium did not demonstrate a survival benefit. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Ipratropium; Pulmonary Disease, Chronic Obstructives; Scopolamine Derivatives Language Published English Country of organisation Canada Province or state Ontario English

2012 Health Technology Assessment (HTA) Database.

470. Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness

three to forty-eight months. Staging of COPD disease severity was based on the degree of airflow limitation as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD). 7 One included trial compared tiotropium to ipratropium in a study of 535 patients and follow up was 52 weeks. Patients were required to have a FEV1 of =65% of the predicted normal value and =70% of FVC, =40 years of age, and smoking history of =10 pack years. Patients were excluded if they had a history of asthma (...) AND POLICY ISSUES Chronic obstructive pulmonary disease (COPD) is a major respiratory illness affecting over 700, 000 Canadians and is preventable and treatable, but not curable. 1 It is the fourth leading cause of death in Canada, with mortality rates increasing over the past fifteen years, especially in women. 2 According to the Canadian Institute for Health Information, COPD accounts for the highest rate of hospital admission and readmission among major chronic diseases in Canada. Exacerbations

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

471. Indacaterol - Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment

Indacaterol - Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment Common Drug Review CDEC Meeting – July 18, 2012 Notice of CDEC Final Recommendation – August 16, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION INDACATEROL MALEATE (Onbrez – Novartis Pharmaceuticals Canada Inc.) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that indacaterol be listed in a similar manner to other long (...) -acting beta2-agonists (LABAs) for the treatment of chronic obstructive pulmonary disease (COPD), at a dose not to exceed 75 mcg per day. Reasons for the Recommendation: 1. In two, 12-week, double-blind randomized controlled trials (RCTs) of patients with moderate to severe COPD, compared with placebo, indacaterol 75 mcg daily was associated with statistically significant improvements in trough forced expiratory volume in one second (FEV 1 ). 2. At recommended doses, the daily cost of indacaterol (75

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

472. Emphysema scores predict death from COPD and lung cancer Full Text available with Trip Pro

Emphysema scores predict death from COPD and lung cancer Our objective was to assess the usefulness of emphysema scores in predicting death from COPD and lung cancer.Emphysema was assessed with low-dose CT scans performed on 9,047 men and women for whom age and smoking history were documented. Each scan was scored according to the presence of emphysema as follows: none, mild, moderate, or marked. Follow-up time was calculated from time of CT scan to time of death or December 31, 2007, whichever (...) came first. Cox regression analysis was used to calculate the hazard ratio (HR) of emphysema as a predictor of death.Median age was 65 years, 4,433 (49%) were men, and 4,133 (46%) were currently smoking or had quit within 5 years. Emphysema was identified in 2,637 (29%) and was a significant predictor of death from COPD (HR, 9.3; 95% CI, 4.3-20.2; P < .0001) and from lung cancer (HR, 1.7; 95% CI, 1.1-2.5; P = .013), even when adjusted for age and smoking history.Visual assessment of emphysema on CT

2012 EvidenceUpdates

473. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison Full Text available with Trip Pro

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison Current guidelines recommend treatment with one or more long-acting bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (COPD). The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic (...) were similar for the treatment groups.Compared with tiotropium monotherapy, indacaterol plus tiotropium provided greater bronchodilation and lung deflation (reflected by increased resting IC). Adverse events were similar between treatments apart from mild cough being more common with indacaterol plus tiotropium. These results support COPD guideline recommendations to combine bronchodilators with different mechanisms of action.NCT00846586 and NCT00877383.

2012 EvidenceUpdates Controlled trial quality: predicted high

474. Multicentre European study for the treatment of advanced emphysema with bronchial valves Full Text available with Trip Pro

Multicentre European study for the treatment of advanced emphysema with bronchial valves This multicentre, blinded, sham-controlled study was performed to assess the safety and effectiveness of bronchial valve therapy using a bilateral upper lobe treatment approach without the goal of lobar atelectasis. Patients with upper lobe predominant severe emphysema were randomised to bronchoscopy with (n = 37) or without (n = 36) IBV Valves for a 3-month blinded phase. A positive responder was defined (...) as having both a ≥ 4-point improvement in St George's Respiratory Questionnaire (SGRQ) and a lobar volume shift as measured by quantitative computed tomography. At 3 months, there were eight (24%) positive responders in the treated group versus none (0%) in the control group (p = 0.002). Also, there was a significant shift in volume in the treated group from the upper lobes (mean ± SD -7.3 ± 9.0%) to the non-treated lobes (6.7 ± 14.5%), with minimal change in the control group (p<0.05). Mean SGRQ total

2012 EvidenceUpdates Controlled trial quality: uncertain

475. Antibiotic Prevention of Acute Exacerbations of COPD. Full Text available with Trip Pro

therapeutic use Forced Expiratory Volume Humans Macrolides adverse effects pharmacology therapeutic use Male Middle Aged Pulmonary Disease, Chronic Obstructive immunology prevention & control Respiratory Function Tests 2012 7 27 6 0 2012 7 27 6 0 2012 8 3 6 0 ppublish 22830464 10.1056/NEJMct1115170 (...) Antibiotic Prevention of Acute Exacerbations of COPD. 22830464 2012 08 02 2012 11 08 1533-4406 367 4 2012 Jul 26 The New England journal of medicine N. Engl. J. Med. Antibiotic prevention of acute exacerbations of COPD. 340-7 10.1056/NEJMct1115170 Wenzel Richard P RP Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, USA. rwenzel@mcvh-vcu.edu Fowler Alpha A AA 3rd Edmond Michael B MB eng Journal Article Review United States N Engl J Med 0255562 0028-4793

2012 NEJM

476. Umeclidinium and vilanterol for chronic obstructive pulmonary disease

Umeclidinium and vilanterol for chronic obstructive pulmonary disease Umeclidinium and vilanterol for chronic obstructive pulmonary disease Umeclidinium and vilanterol for chronic obstructive pulmonary disease NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Umeclidinium and vilanterol for chronic obstructive pulmonary disease (...) . Birmingham: National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Chronic Disease; Pulmonary Disease, Chronic Obstructives Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University

2012 Health Technology Assessment (HTA) Database.

477. Effects of an uncertainty management intervention on uncertainty, anxiety, depression, and quality of life of chronic obstructive pulmonary disease outpatients (Abstract)

Effects of an uncertainty management intervention on uncertainty, anxiety, depression, and quality of life of chronic obstructive pulmonary disease outpatients In this controlled, randomized study we explored the effects of an uncertainty management intervention on uncertainty, anxiety, depression, and quality of life (QOL) of chronic obstructive pulmonary disease (COPD) outpatients in China. Ninety-six COPD outpatients completed the study (n = 49 in the intervention group; n = 47 (...) in the control group). Over the 10-month study duration, the intervention group received a cognitive behavioral intervention. Compared with the control group, the intervention group showed significant improvement in uncertainty, coping strategy, anxiety, depression, and the mental health domains of QOL after the intervention, providing the first evidence that uncertainty management can improve the emotional status and QOL of COPD outpatients.Copyright © 2012 Wiley Periodicals, Inc.

2012 EvidenceUpdates Controlled trial quality: uncertain

478. Interventions to support a palliative care approach in patients with chronic obstructive pulmonary disease: An integrative review (Abstract)

Interventions to support a palliative care approach in patients with chronic obstructive pulmonary disease: An integrative review End-stage chronic obstructive pulmonary disease (COPD) is a debilitating, life-limiting condition. A palliative approach is appropriate for individuals with end-stage COPD, yet currently few interventions embrace this holistic, multidisciplinary and inclusive perspective.To describe interventions to support a palliative care approach in patients with end-stage (...) for discrete elements of palliative management in this patient group, there is limited evidence for health service coordination and models that integrate the multiple domains of palliative care with active management.Further investigation is required to address the complex personal, provider and system elements associated with managing end-stage COPD. A comprehensive and collaborative approach is required to address the complex and varied needs of individuals with end-stage COPD

2012 EvidenceUpdates

479. Interventions for Chronic Obstructive Pulmonary Disease Patients in a Hospital Setting: Clinical Effectiveness and Guidelines

Interventions for Chronic Obstructive Pulmonary Disease Patients in a Hospital Setting: Clinical Effectiveness and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts (...) systematic reviews, 10 randomized controlled trials, seven non-randomized studies, and four evidence-based guidelines were identified regarding interventions for chronic obstructive pulmonary disease patients for reducing length of stay in a hospital setting. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2012, Issue 4), University of York Centre for Reviews and Dissemination (CRD), ECRI (Health Devices Gold) databases, Canadian and major

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

480. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD Full Text available with Trip Pro

Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD Rates of mortality and readmission are high in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). In this population, the prognostic value of the Medical Research Council Dyspnoea Scale (MRCD) is uncertain, and an extended MRCD (eMRCD) scale has been proposed to improve its utility. Coexistent pneumonia is common and, although

2012 EvidenceUpdates